A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/without prior use of glucagon-like peptide-1 receptor agonist therapy
Authors' conclusion
Treatment advancement with Gla-300 in patients with T2D, with/without prior GLP-1 RA therapy, improved glycaemic outcomes with no relevant impact on weight, while maintaining a low hypoglycaemia risk.
Study context
- Population
- Insulin-naïve people with T2D intensifying with insulin glargine 300 U/mL (Gla-300)3 analyses
- Participants
- 3,562 people
- Comparison
- Gla-300 with vs without prior GLP-1 RA therapy
- Outcome
- HbA1c LS mean change from baseline
Methodological detailspooled analysis of seven interventional studies, subanalysis, expanded analysis including two observational studies
- Pooled analysis of seven interventional studies
- Subanalysis
- Expanded analysis including two observational studies
Pooled result
As reported in the abstract
Prior GLP-1 RA
- 1.7
least squares mean · %
No prior GLP-1 RA
- 1.6
least squares mean · %
Further pooled results
Stopped GLP-1 RA and initiated Gla-300 vs add-on Gla-300 (subanalysis)
- Glycaemic outcomes similar; more participants receiving add-on Gla-300 achieved HbA1c targets
Expanded analysis incl. two observational studies
- Similar results
Safety
- Low incidence of hypoglycaemia, no clinically relevant weight changes in all analyses
Original publication
A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/without prior use of glucagon-like peptide-1 receptor agonist therapy. Diabetes Res Clin Pract. Published 27 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →